Email Us (925) 376-0217
Login  |  Signup (0)
Register Now
Register Now

Faculty

Lynette M. Sholl [M.D.]

  • Titles : Assistant Professor, Pathology, Harvard Medical School, Associate Pathologist, Brigham And Women's Hospital
  • Affiliations : Brigham and Women's Hospital

  • Graduated from Johns Hopkins University in 1998
  • Graduated from Stanford University School of Medicine in 2003
  • Board Certified in Anatomic Pathology and Molecular Genetic Pathology 
  • Associate Director, Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital 
  • Chief, Pulmonary Pathology Division at Brigham and Women’s Hospital


Reformed long distance runner

Raising happy and healthy children

Peer Reviewed
 
  1. Sholl LM, Hornick, JL, Pinkus JL, Pinkus GS, Padera RF.  Immunohistochemical analysis of Langerin in Langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases.  Am J Surg Pathol.  2007; 31(6):947-952.
  2. Sholl LM, Iafrate AJ, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol. 2007;20(10):1028-1035. 
  3. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M Zhou, X, Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-3028. 
  4. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.  Cancer Res. 2009; 69(21):8341-8348.
  5. Sholl LM, Long KB, Hornick JL.  Sox2 expression in non small cell and pulmonary neuroendocrine carcinomas.  Appl Immunohistochem Mol Morphol. 2010; 18(1):55-61.
  6. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon A, Pan B-S, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in Non-Small Cell Lung Cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.  Am J Pathol. 2010; 177(1):415-423.
  7. Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi L, Jackman, D,  Lee, C,  Jänne, P,  Lindeman, N. EGFR Mutation is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma than FISH, CISH, or Immunohistochemistry. Am J Clin Path. 2010; 133(6):922-934.
  8. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 Protein Expression Is an Independent Poor Prognostic Indicator in Stage I Lung Adenocarcinomas.  Am J Surg Pathol. 2010; 34(8):1193-1198.
  9. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, Day E, Toews GB, Joshi AD, Schaller MA, Waters B, Jarai G, Westwick J, Kunkel SL, Martinez FJ, Hogaboam CM. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med. 2010;2(57):57ra82.
Reviews/Book Chapters
  1. Sholl LM. Large Cell Carcinoma: A Lung Carcinoma Redefined by Immunohistochemistry and Genomics (Invited Review). Cur Opin in Pulm Pathol. 2014 Jul;20(4):324-331.
  2. Sholl LM.  Predictive Immunohistochemistry in Lung Adenocarcinoma.  (Invited Review). Sem in Diag Pathol. 2015 Feb 4;S0740-2570.
  3. Sholl LM, Lindeman N. Molecular Pathology of Lung Cancers (chapter) in Molecular Surgical Pathology, Cheng, L. and Eble, J.N. eds. New York: Springer 2013.
  4. Sholl LM, Hornick JL. Diagnosis of Primary and Metastatic Germ Cell Tumors Using Embryonic Stem Cell Transcription Factors (chapter) in Stem Cells and Cancer Stem Cells, Volume 9. Hayat, M.A., ed. New York: Springer 2013.
  5. Vivero M, Sholl LM.  Epidemiology of Malignant Mesothelioma (chapter) in Diffuse Malignant Mesothelioma. Allen, T., ed. Springer 2015.
  6. Nicholson A, Rekhtman N, Geisinger K, Sholl LM et al. Large Cell Carcinoma.  Entry in World Health Organization 5th edition Classification of Lung Tumors. 2015.
  7. Chirieac L, French C, Sholl LM. Nut Midline Carcinoma of the Lung. Entry in World Health Organization 5th edition Classification of Lung Tumors. 2015.
  8. Sholl LM, Nishino, M.  Adenocarcinoma (chapter) in Lung and Pleural Pathology. Cagle, P. and Allen, T., eds.  McGraw-Hill 2015.
Editorials
  1. Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y. Programmed Death Ligand 1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.Programmed Death Ligand 1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med. 2016 Jan 18. [Epub ahead of print]

 
 

  • 4th Annual Richard L. Kempson Diagnostic Pathology Course: More Pathology Top Ten Topics

Past Lectures

  • The Pathologist's Role in Immune Therapy (07/19/2018)
  • Managing Small Biopsies for Lung Cancer Diagnosis and Molecular Testing (07/19/2018)
  • Liquid Biopsy for Lung Cancer: Implications for Surgical Pathology Practice (07/18/2018)
  • HPV-Related Squamous Lesions of Head & Neck: Cytology, Histology & HPV Assays (07/18/2018)
  • Update on Fibrosing Disease of the Lung (07/17/2018)
  • Practical Guide to the Pathology of Pulmonary Ground Glass Modules (07/16/2018)

X


Welcome to Scientific Symposiums International

We hope you find the new website to have all the valuable content and information you need.

Please let us know if you have any feedback!

Enter your email to receive the latest news, updates and promotions for our upcoming courses!

Continue